Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $1,247.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)September 25, 2024 7:15 AM Piper Sandler are buyers of this biotech stock despite ongoing selloff September 25, 2024 6:00 AM Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'September 24, 2024 2:18 PM Regeneron slump continues as analysts turn more cautiousSeptember 24, 2024 12:16 PM Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'Eylea Franchise Outlook Uncertain'September 24, 2024 6:03 AM Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)September 24, 2024 5:30 AM Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)September 24, 2024 5:28 AM